Skip to main content
NKTR
NASDAQ Life Sciences

Nektar's Q2 2026: $1.02B Cash, Phase 3 ZENITH AD Underway, Runway to Q3 2028

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$76.3
Mkt Cap
$2.565B
52W Low
$23.675
52W High
$109
52W Position info
222% above low
Off High info
30% below high
Rel. Volume info
0.6× avg
Market data snapshot near publication time

NKTR has more than doubled off its 52-week low of $23.675.

Summary

Nektar Therapeutics reported Q2 2026 results with $1.02 billion in cash, initiated Phase 3 ZENITH AD trials, and extended cash runway into Q3 2028.


Key Events · Earnings and Guidance · NKTR

  • Q2 2026 Financial Results

    Revenue of $10.1 million, net loss of $40.6 million ($1.23 per share), and cash/investments of $1,023.4 million as of June 30, 2026.

  • Cash Runway Extended

    Cash runway extends into Q3 2028, past initial Phase 3 data readouts expected in mid-2028.

  • Phase 3 ZENITH AD Initiated

    First two global registrational trials in atopic dermatitis initiated in July 2026; third trial to enroll patients with prior biologic/JAK inhibitor experience.

  • Alopecia Areata Phase 3 Planned

    Single registrational Phase 3 study in alopecia areata planned to start in early 2027.


Analysis · NKTR · Life Sciences

A robust financial position underpins Nektar's Q2 2026 results, with over $1 billion in cash and investments extending the runway into Q3 2028. The company has initiated its Phase 3 ZENITH AD program in atopic dermatitis and plans a registrational Phase 3 study in alopecia areata in early 2027, targeting a first BLA submission for 2029. R&D spending increased significantly to support these trials, while G&A costs declined. Net loss per share improved to $1.23 from $2.95 year-over-year, reflecting the impact of the April 2026 equity offering that increased shares outstanding.

How filings like this one have moved

In the 30 days to Nov 11, 2026, 36.6% of the 3434 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, NKTR was trading at $76.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.6B. The 52-week trading range was $23.68 to $109.00. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

NKTR - Latest Insights

NKTR
Oct 01, 2026, 11:45 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $48.58
Real-time Price: $38.40 info
Change: -$10.18 (-21%) info
Market Cap: $1.312B info
NKTR
Oct 01, 2026, 7:57 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $60.70
Real-time Price: $38.40 info
Change: -$22.30 (-37%) info
Market Cap: $1.312B info
NKTR
Oct 01, 2026, 7:31 AM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $60.50
Real-time Price: $38.40 info
Change: -$22.10 (-37%) info
Market Cap: $1.312B info
NKTR
Sep 25, 2026, 7:00 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $62.26
Real-time Price: $38.40 info
Change: -$23.86 (-38%) info
Market Cap: $1.312B info
NKTR
Sep 22, 2026, 3:17 PM EDT
Source: Seeking Alpha
Importance Score:
7
Price at Filing: $61.22
Real-time Price: $38.40 info
Change: -$22.82 (-37%) info
Market Cap: $1.312B info